Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Fujitsu begins two-year medical AI research project

Partners with Kyoto University on R&D-focused work

Artificial intelligence AI pharma healthcare

Japanese IT company Fujitsu is collaborating with Kyoto University on a two-year project to investigate the use of artificial intelligence in medicine.

The partners are focused on AI’s possibilities in accelerating the research and development of next-generation medicine, such as new approaches to diagnostics and drug discovery.

The work will be run from the newly-established Department of Medical Intelligent Systems within Kyoto University.

The medical information put to use will include cancer patient data and patient data from electronic medical records collected by Kyoto University Hospital.

The firms say that existing AI technology has yet to adequately integrated the huge volumes of data from sources such as electronic medical records, medical journals and genomic data.

“To put this data to use, it has become essential to develop AI for medicine through the close collaboration of researchers with a high degree of knowledge of the medical field with AI researchers and engineers,” Fujitsu said in a statement.

Meanwhile, last year saw an uptick in life sciences interest in applying AI to drug research, with the likes of Scotland’s Exscientia scoring deals with GSK, Evotec and Sanofi, and Lundbeck signing up with IBM Watson Health.

1st February 2018

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...